Search

Your search keyword '"Nanetti L"' showing total 374 results

Search Constraints

Start Over You searched for: Author "Nanetti L" Remove constraint Author: "Nanetti L"
374 results on '"Nanetti L"'

Search Results

3. Extreme phenotypic heterogeneity in non-expansion spinocerebellar ataxias.

4. Neuro-telehealth for fragile patients in a tertiary referral neurological institute during the COVID-19 pandemic in Milan, Lombardy

5. Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study

6. Predictors of malnutrition risk in neurodegenerative diseases: The role of swallowing function

7. Multifaceted and Age-Dependent Phenotypes Associated With Biallelic PNPLA6 Gene Variants: Eight Novel Cases and Review of the Literature

8. Comorbidities in Friedreich ataxia: incidence and manifestations from early to advanced disease stages

11. Is overwork weakness relevant in Charcot–Marie–Tooth disease?

12. PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot–Marie–Tooth 1A biomarker

27. Prediction of Survival With Long-Term Disease Progression in Most Common Spinocerebellar Ataxia

33. Suicidal ideation in a European Huntington's disease population

34. Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia

35. The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients

36. Responsiveness of clinical outcome measures in Charcot-Marie-Tooth disease

37. Whole body cholesterol metabolism is impaired in Huntington's disease

38. Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY

39. NMDA receptor gene variations as modifiers in Huntington disease: a replication study

40. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial

41. Cerebral and extracerebral cholesterol biosynthesis is impaired in HD patients

42. Is overwork weakness relevant in Charcot-Marie-Tooth disease?

43. PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker

44. Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients

46. Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study

48. β-Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington's Disease

49. Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations

50. Discrepancies in reporting the CAG repeat lengths for Huntington's disease

Catalog

Books, media, physical & digital resources